All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity DOI Creative Commons
Ariel Ramírez-Labrada, Cecilia Pesini, Llipsy Santiago

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: May 16, 2022

NK cells are key mediators of immune cell-mediated cytotoxicity toward infected and transformed cells, being one the main executors cell death in system. recognize target through an array inhibitory activating receptors for endogenous or exogenous pathogen-derived ligands, which together with adhesion molecules form a structure known as immunological synapse that regulates effector functions. The best characterized mechanisms involved granule exocytosis pathway (perforin/granzymes) expression ligands. These pathways recognized activators different programmes on leading to their destruction. However, most studies analyzing these have used pure recombinant native proteins instead intact and, thus, extrapolation results might be difficult. Specially, since activation and/or ligands during elimination influenced by stimulus received from other microenvironment components, affect activated cells. Here we will review discuss available experimental evidence how kill special focus modalities been found cytotoxicity; including apoptosis more inflammatory like necroptosis pyroptosis. In light this new evidence, develop concept induced regulatory mechanism linking innate response tumour adaptive T responses, initiating trigger cancer-immunity cycle. use modulation molecular machinery regulating them not only but, addition, generation responses against would contribute efficient generate cancer memory preventing potential recurrences.

Language: Английский

NK cells for cancer immunotherapy DOI
Noriko Shimasaki, Amit Jain, Dario Campana

et al.

Nature Reviews Drug Discovery, Journal Year: 2020, Volume and Issue: 19(3), P. 200 - 218

Published: Jan. 6, 2020

Language: Английский

Citations

973
Exploring the NK cell platform for cancer immunotherapy DOI
Jacob A. Myers, Jeffrey S. Miller

Nature Reviews Clinical Oncology, Journal Year: 2020, Volume and Issue: 18(2), P. 85 - 100

Published: Sept. 15, 2020

Language: Английский

Citations

931
The cancer–natural killer cell immunity cycle DOI
Nicholas D. Huntington, Joseph Cursons, Jai Rautela

et al.

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 20(8), P. 437 - 454

Published: June 24, 2020

Language: Английский

Citations

448
Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma DOI Open Access

Hamid Maadi,

Mohammad Hasan Soheilifar, Wonshik Choi

et al.

Cancers, Journal Year: 2021, Volume and Issue: 13(14), P. 3540 - 3540

Published: July 15, 2021

Trastuzumab as a first HER2-targeted therapy for the treatment of HER2-positive breast cancer patients was introduced in 1998. Although trastuzumab has opened new avenue to treat with and other types cancer, some are not responsive or become resistant this treatment. So far, several mechanisms have been suggested mode action trastuzumab; however, findings regarding these controversial. In review, we aimed provide detailed insight into various trastuzumab.

Language: Английский

Citations

121
Cell death, therapeutics, and the immune response in cancer DOI Creative Commons
Kay Hänggi, Brian Ruffell

Trends in cancer, Journal Year: 2023, Volume and Issue: 9(5), P. 381 - 396

Published: Feb. 24, 2023

Language: Английский

Citations

110
The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer DOI Creative Commons

Hans Klingemann

Cytotherapy, Journal Year: 2023, Volume and Issue: 25(5), P. 451 - 457

Published: Jan. 6, 2023

The NK-92 cell line, established in 1992, mirrors all the characteristics of highly active blood natural killer (NK) cells but with much broader and greater cytotoxicity. line was from a patient lymphoma has been made widely available for research since it deposited into American Type Culture Collection 1998. worldwide distribution led to plethora scientific discoveries that have greatly increased understanding NK-cell biology. also developed clinical use, overcoming challenges obtaining expanding NK donor or blood. More than 100 patients cancer now treated over world unmodified genetically engineered cells. Modified include high-affinity Fc-receptor expressing (haNKR) various chimeric antigen receptor targeted haNK (t-haNKTM). Infusions either modified reported be safe efficacious, leading some cases disease remission even who had failed multiple previous lines therapy. It is purpose this review distill data on its genetic variants, highlighting relevant experimental findings contributed better biology summarize therapeutic potential these treatment infections.

Language: Английский

Citations

67
Innate lymphoid cells and innate-like T cells in cancer — at the crossroads of innate and adaptive immunity DOI
Benjamin Ruf, Tim F. Greten, Firouzeh Korangy

et al.

Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(6), P. 351 - 371

Published: April 20, 2023

Language: Английский

Citations

52
Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches DOI Creative Commons
Yaxian Wang, Xinyang Zhong, Xuefeng He

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 42(1)

Published: July 22, 2023

Colorectal cancer liver metastasis (CRLM) is one of the leading causes death among patients with colorectal (CRC). Although immunotherapy has demonstrated encouraging outcomes in CRC, its benefits are minimal CRLM. The complex immune landscape hepatic tumour microenvironment essential for development a premetastatic niche and colonisation CRC cells; thus, an in-depth understanding these mechanisms can provide effective immunotherapeutic targets This review summarises recent studies on CRLM highlights therapeutic prospects targeting suppressive

Language: Английский

Citations

43
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors DOI Creative Commons
Lei Peng, Giacomo Sferruzza,

Luojia Yang

et al.

Cellular and Molecular Immunology, Journal Year: 2024, Volume and Issue: 21(10), P. 1089 - 1108

Published: Aug. 12, 2024

Abstract In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach for combating cancers, demonstrating remarkable efficacy in relapsed/refractory hematological malignancies both pediatric and adult patients. CAR-natural killer (CAR-NK) complements CAR-T by offering several distinct advantages. CAR-NK cells do not require HLA compatibility exhibit low safety concerns. Moreover, are conducive to “off-the-shelf” therapeutics, providing significant logistic advantages over cells. Both have shown consistent results malignancies. However, their against solid tumors remains limited due various obstacles including tumor trafficking infiltration, well an immuno-suppressive microenvironment. this review, we discuss recent advances current challenges of immunotherapies, with specific focus on application tumors. We also analyze depth drawbacks compared highlight CAR optimization. Finally, explore future perspectives these adoptive highlighting increasing contribution cutting-edge biotechnological tools shaping next generation cellular immunotherapy.

Language: Английский

Citations

38
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside DOI Creative Commons
Beibei Zhang, Mengzhe Yang, Weimin Zhang

et al.

Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(1)

Published: Jan. 15, 2024

Abstract Immunotherapy has rapidly evolved in the past decades battle against cancer. Chimeric antigen receptor (CAR)-engineered T cells have demonstrated significant success certain hematologic malignancies, although they still face limitations, including high costs and toxic effects. Natural killer (NK cells), as a vital component of immune system, serve “first responders” context cancer development. In this literature review, we provide an updated understanding NK cell development, functions, their applications disease therapy. Furthermore, explore rationale for utilizing engineered therapies, such CAR-NK cells, discuss differences between CAR-T cells. We also insights into key elements strategies involved CAR design addition, highlight challenges currently encountered future directions research utilization, pre-clinical investigations ongoing clinical trials. Based on outstanding antitumor potential it is highly likely that will lead to groundbreaking advancements treatment future.

Language: Английский

Citations

30